Investor Relations

Print Print page     Email Email page

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Our lead product, Remodulin®, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin®, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as dengue and influenza. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Jul 29, 2014
United Therapeutics Corporation Reports Second Quarter 2014 Financial Results

Jul 22, 2014
United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014

more »


Sep 8, 2014
Rodman & Renshaw 16th Annual Global Investment Conference

Sep 8, 2014
2014 Morgan Stanley Global Healthcare Conference

Oct 1, 2014
Leerink Partners Rare Disease Roundtable

more »